Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks.
Sarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, Jose Carlos Benitez, Alice Durand, Helene Lasolle, Marine Perrier, Arnaud Jannin, Sandrine Laboureau, Maelle Le Bras, Olivier Chabre, Sébastien Gaujoux, Lionel Groussin Rouiller, Olivia Hentic, Hélène Du Boullay, Magalie Haissaguerre, Hervé Kinn, Thierry Lecomte, Pierre Goudet, Nicolas Girard, Jean-Yves Scoazec, Benjamin Besse, Matthieu Faron, Eric Baudin
{"title":"Characterization, Prognosis, and Treatment of Patients With Locally Advanced or Metastatic Thymic Neuroendocrine Tumor: A Retrospective Study of the French GTE, ENDOCAN RENATEN, and RYTHMIC Networks.","authors":"Sarah Fodil-Cherif, Julien Hadoux, Olaf Mercier, Jose Carlos Benitez, Alice Durand, Helene Lasolle, Marine Perrier, Arnaud Jannin, Sandrine Laboureau, Maelle Le Bras, Olivier Chabre, Sébastien Gaujoux, Lionel Groussin Rouiller, Olivia Hentic, Hélène Du Boullay, Magalie Haissaguerre, Hervé Kinn, Thierry Lecomte, Pierre Goudet, Nicolas Girard, Jean-Yves Scoazec, Benjamin Besse, Matthieu Faron, Eric Baudin","doi":"10.1016/j.jtho.2025.04.013","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Thymic neuroendocrine tumors (Thy-NETs) constitute a poorly characterized ultrarare subgroup of NET. To characterize locally advanced or metastatic Thy-NET, to evaluate prognostic factors for survival, and to provide an overview of their current therapeutic management in two dedicated French national networks.</p><p><strong>Methods: </strong>Retrospective multicenter study of two French ENDOCAN-RENATEN and RYTHMIC networks.</p><p><strong>Results: </strong>A total of 74 patients (median age, 46 y) followed in 20 French centers between 1988 and 2020 were included. Main characteristics were as follows: male over female ratio of 2.7, multiple endocrine neoplasia type 1 inherited syndrome in 25 patients (34%), NET G2 atypical carcinoids in 31 patients (48%), 20 patients (31%) with NET G3 highly proliferative atypical carcinoids, and 11 patients (15%) with ectopic Cushing syndrome. Metastatic sites were as follows: lymph nodes (54 patients, 73%), bone (42 patients, 65%), lung (31 patients, 42%), and pleura (31 patients, 42%). A total of 64 patients (87%) had locally advanced Thy-NET and eight (11%) had synchronous metastases, at diagnosis. Pleural metastases were almost exclusively metachronous. Positive results for 18F-FDG or somatostain receptor imaging was found in 88% or 74% of cases, respectively. The 5-year overall survival was 85%. Univariate analysis on overall survival reveals a trend toward worse prognosis in case of female gender and bone metastases and better prognosis for patients with multiple endocrine neoplasia type 1. Partial responses were more frequently observed in patients treated with cytotoxic chemotherapy.</p><p><strong>Conclusion: </strong>This large series identifies specific characteristics of patients with advanced Thy-NET. Prognosis was better than previously reported. Perioperative pleural dissemination is suspected. Partial responses were mainly observed with chemotherapy.</p>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":" ","pages":""},"PeriodicalIF":20.8000,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jtho.2025.04.013","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Thymic neuroendocrine tumors (Thy-NETs) constitute a poorly characterized ultrarare subgroup of NET. To characterize locally advanced or metastatic Thy-NET, to evaluate prognostic factors for survival, and to provide an overview of their current therapeutic management in two dedicated French national networks.
Methods: Retrospective multicenter study of two French ENDOCAN-RENATEN and RYTHMIC networks.
Results: A total of 74 patients (median age, 46 y) followed in 20 French centers between 1988 and 2020 were included. Main characteristics were as follows: male over female ratio of 2.7, multiple endocrine neoplasia type 1 inherited syndrome in 25 patients (34%), NET G2 atypical carcinoids in 31 patients (48%), 20 patients (31%) with NET G3 highly proliferative atypical carcinoids, and 11 patients (15%) with ectopic Cushing syndrome. Metastatic sites were as follows: lymph nodes (54 patients, 73%), bone (42 patients, 65%), lung (31 patients, 42%), and pleura (31 patients, 42%). A total of 64 patients (87%) had locally advanced Thy-NET and eight (11%) had synchronous metastases, at diagnosis. Pleural metastases were almost exclusively metachronous. Positive results for 18F-FDG or somatostain receptor imaging was found in 88% or 74% of cases, respectively. The 5-year overall survival was 85%. Univariate analysis on overall survival reveals a trend toward worse prognosis in case of female gender and bone metastases and better prognosis for patients with multiple endocrine neoplasia type 1. Partial responses were more frequently observed in patients treated with cytotoxic chemotherapy.
Conclusion: This large series identifies specific characteristics of patients with advanced Thy-NET. Prognosis was better than previously reported. Perioperative pleural dissemination is suspected. Partial responses were mainly observed with chemotherapy.
期刊介绍：
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
